United Therapeutics

United Therapeutics Corporation is a biotechnology company founded in 1996 and based in Silver Spring, Maryland. The company is dedicated to developing innovative treatments for chronic illnesses, particularly Pulmonary Arterial Hypertension (PAH) and other rare diseases. It has achieved significant milestones, including the approval of several drugs for PAH, such as Remodulin, Orenitram, and Tyvaso, as well as Unituxin for high-risk neuroblastoma. The company emphasizes research and development, investing $412 million annually to create novel therapies and technologies. United Therapeutics is also exploring advancements in organ bioprinting and ex-vivo lung perfusion to enhance the availability of transplantable organs. With a strong commitment to patient safety and access to medicine, United Therapeutics aims to address the needs of patients with rare and chronic diseases. As of 2023, the company reported a revenue of $2.1 billion and employed approximately 1,237 people.